OCEANSIDE, Calif. -- (March 10, 2011) -- International Stem Cell Corporation (OTCBB:ISCO), www.internationalstemcell.com, announced today that its Executive Chairman, Kenneth C. Aldrich, will present at the ROTH 23rd Annual Orange County Growth Stock Conference at the Ritz Carlton Laguna Niguel in Dana Point, CA. on Wednesday, March 16, 2011 at 10:30 AM PDT (1:30 PM EDT). The webcast can be viewed live at: http://www.wsw.com/webcast/roth24/isco/. The presentation will be archived and viewable at the same link for 90 days. After the Roth Conference, a link to the presentation will also be posted to the ISCO website, www.internationalstemcell.com.
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)
International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and has developed cell based skin care products through its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO's website, www.internationalstemcell.com.
Key Words: Stem cells, parthenogenesis, biotechnology, skin care
International Stem Cell Corporation
Kenneth C. Aldrich, Executive Chairman